About Us

Our Vision

A pioneering platform sharing independent, expert and practical CAR-T cell therapy knowledge curated by Australian leaders in the CAR-T field.

Our goal is for CAR-T Central to be regarded by the Australian haematology community as a trusted source of information, clinical resources and expert opinion.

Our Mission

The mission of CAR-T Central is to promote excellence in patient care by furthering understanding of CAR-T therapy, with up-to-date information on the options and treatment centres available in Australia and provide practical guidance on the clinical use of CAR-T therapy.

Core Values

EXCELLENCE in the quality of information provided

TRUST and TRANSPARENCY as an independent and reliable source of expert knowledge focusing on treatment benefits for cancer patients

RELEVANCE A targeted, audience-specific platform providing highly relevant and timely information underpinning the practical realities of CAR-T therapy


The CAR-T Steering Committee have final approval on all content except in the circumstance where publication of material would create a breach of Australian laws.

Opinions expressed on CAR-T Central and in related materials and publications, are those of the Steering Committee, or other contributing consultants, and not those of Bastion Med Ed or the sponsor, except where otherwise specifically acknowledged.

Educational and product specific information provided on this site are for education purposes and to aid clinical decision making. Any clinical decisions made by healthcare professionals on the basis of information on this site are the responsibility of those healthcare professionals alone. All available information relating to the management of patients should be considered prior to making clinical decisions, including the use of any specific products.
Steering Committee
    Westmead Hospital/ Westmead Institute, NSW
    Icon Cancer Centre & Royal Brisbane Hospital, QLD
    Peter MacCallum Cancer Centre, VIC
    Sydney Children’s Hospital, NSW
    Epworth Healthcare, VIC
    Fiona Stanley Hospital, WA
    Royal Prince Alfred Hospital, NSW
    Peter MacCallum Cancer Centre, VIC
Westmead Hospital/ Westmead Institute, NSW

Associate Professor Blyth is the Clinical Lead for Immune Effector Cells at Westmead Hospital in NSW. She is a haematologist, bone marrow transplant and cell therapy physician and a post-doctoral research fellow at the Westmead Institute for Medical Research at the University of Sydney. She has a clinical interest in transplant and cellular therapies. She is a Research Lead in the Westmead Cell Therapies Group’s clinical trial program and a member of the Sydney Cell and Gene Therapy Strategic Committee which is focused on bringing cell and gene therapy technologies to patients in clinical trials at the Westmead Campus. Her research interests are in the use of cellular therapy to improve quality of life and survival in patients with blood cancers and those undergoing blood stem cell transplantation.

Icon Cancer Centre & Royal Brisbane Hospital

Dr Jason Butler is a senior staff specialist at the Bone Marrow Transplant Unit, Royal Brisbane and Women’s Hospital and Visiting Haematologist with Icon Cancer Centre. Dr Butler also completed a Masters in Medical Science (Clinical Epidemiology) to assist with development of investigator-initiator research studies. He is the chair of the EviQ haematology reference committee. His major clinical interests are in all aspects of malignant haematology, particularly in leukaemia, lymphoma, and myeloma, CAR T therapy, as well as autologous and allogeneic stem cell transplantation, including investigator roles on clinical studies in each of these fields. Dr Butler also undertakes other roles, including extensive educational support and clinical presentations for patients and health professionals, and advocacy roles as a board member for Lymphoma Australia.

Peter MacCallum Cancer Centre, Victoria

Dr Michael Dickinson is the Lead of the Aggressive Lymphoma disease group within Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital.   He specialises as a principal investigator in phase I/II clinical trials of new anti-cancer drugs with a current focus on Aggressive Lymphomas and novel immunotherapies, but with experience across a breadth of haematological malignancies. His investigator- initiated studies have focused on the role of epigenetic modifiers in haematological malignancies,  eltrombopag as a supportive care agent in MDS/AML, and new CAR-T therapies.  Michael’s clinical research includes industry and investigator-led trials in aggressive lymphoma, phase 1 studies, and CAR-T trials.

Sydney Children’s Hospital

Professor Tracey O’Brien is a paediatric and adolescent oncologist, Director of the Kids Cancer Centre (KCC) and Director of the Transplant & Cellular Therapies Program at Sydney Children’s Hospital, Randwick. Tracey has over 100 peer reviewed publications and holds a number of national and international leadership positions including Chair of the Advisory Board of Cancer Australia, Vice Chair, (Africa, Asia and Australia) of the International Centre for Bone Marrow Transplant Research (CIBMTR) Advisory Board, Director,ANZ Transplant and Cellular therapy group, board director for Children’s Cancer Institute and has served as past Vice chair for the ANZ Children’s Haematology & Oncology Group (ANZCHOG). In addition to medical training, Tracey has a Master of Health Law, an MBA and in 2019, was named in the top 10 Australian Women of Influence AFR Awards, winning the innovation category.

Epworth Healthcare

Miles is the Professor/Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and a previous Director of the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre after establishing the Centre in 1999. He also oversees clinical and laboratory research – the latter involving stem cell research, genomics and cancer immunology and is lead investigator for a large NHMRC Program Grant in Cancer Immunology. He has been the Principal Investigator of over 200 clinical trials in myeloma, lymphoma and leukaemia and led the first CAR-T study in Australia over 10 years ago in AML. He has published over 450 peer- reviewed manuscripts. He is one of the establishing members of the Snowdome Foundation which focuses on accelerating new therapies for Australian patients with blood cancers. He is a Fellow of the Academy of Health & Medical Sciences and a Member of the Order of Australia.

Fiona Stanley Hospital, Western Australia.

Dr Duncan Purtill is a consultant haematologist at Fiona Stanley Hospital, WA. He trained in WA and undertook fellowships at Hôpital Saint Louis, Paris, and Memorial Sloan Kettering Cancer Centre, New York. His interests are in stem cell transplantation and cellular therapies, and promoting the role of quality management and patient registries in clinical practice.

Royal Prince Alfred Hospital, NSW

Professor John Rasko is an Australian pioneer in the application of stem cells and genetic therapies. For over two decades he has directed the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital and the Gene and Stem Cell Therapy Program at the Centenary Institute, University of Sydney. As a clinical haematologist, pathologist and scientist he has contributed to the understanding of stem cells and blood cell development, gene therapies, cancer causation and treatment, human genetic diseases and molecular biology. John frequently appears on radio and television to discuss biomedical research, medical tourism, and scientific fraud. He delivered the prestigious 2018 Boyer Lecture series for the Australian Broadcasting Commission. Service to national and international professional societies, as well as a series of prestigious awards, recognise his commitment to excellence in medical research, including appointment as an Officer of the Order of Australia.

Peter MacCallum Cancer Centre, Victoria

Professor Con Tam is Clinical Lead for CLL and Low-Grade Lymphoma at Peter MacCallum Cancer Centre and Professor of Haematology at the University of Melbourne. He has a keen interest in the biology and treatment of blood cancers. Professor Tam has extensive experience in the conduct of clinical trials, particularly those involving new targeted therapies. He is the global lead for the novel BTK inhibitor zanubrutinib, and he completed the first study in the world to combine ibrutinib and venetoclax (published in New England Journal of Medicine in 2018). Professor Tam participates actively in peer- review and is Associate Editor of Blood Advances. Since 2012, Professor Tam has received over $18 million in grants. He has authored 179 papers, with over 5000 Web of ScienceTM citations. Professor Tam is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Hematology Association.

Bristol Myers Squibb


If you would like to discuss sponsorship opportunities please contact Bastion MedEd.
Contact Us

If you have an enquiry for the steering committee please include your message below with your contact details.

Contact Us

CAR-T Central is a Bastion Med Ed Initiative

To contact the Bastion Med Ed team:



+61 (3) 8592 1234

115 Green Street, Cremorne VIC 3121



+61 (3) 8592 1234

The Commons Central, 20-40 Meagher St, Chippendale NSW 2008